Which longevity startup is growing the fastest?

Last updated: 28 October 2026
Cover of NewMarketPitch's Longevity: Who's Ahead report Which checkup startups have the most members? Function Health says it has the most, 500,000+ members, ahead of Prenuvo’s 110,000+. None of them publishes how many members pay today. Chart from NewMarketPitch’s Longevity report.Neko or Function: who leads the longevity checkup? Function on people, 500,000+ members, and on sales, ~$100M (an estimate). Neko on money, $960M raised and a ~$7B value. Chart from NewMarketPitch's Longevity report.How fast are the top longevity startups rising in value? Fast. Function’s value rose ~10 times in 17 months, to $2.5B. Neko and NewLimit nearly quadrupled in 13 to 18 months, NewLimit with no drug in people. Chart from NewMarketPitch's Longevity report.How fast is Neko Health growing, clinic by clinic? Fast, from one clinic in Stockholm in 2023 to nine in Sweden, the UK and New York, with 100,000+ people scanned by July 2026. Miami and a second New York clinic are planned by January 2027. Chart from NewMarketPitch’s Longevity report.Which body-scan startups scan the most people? Prenuvo publishes the biggest count, 200,000+ MRI scans done by September 2026. Neko says 100,000+ people scanned by July 2026, while Ezra and Craft Body Scan publish no count. Chart from NewMarketPitch’s Longevity report.Is Neko Health, the body-scan startup, really worth $7 billion? Not on sales, mostly on promise. Neko sold ~$16M of body scans in 2025 and lost ~$70M. At ~$7B, it is valued at 430 times its sales. Chart from NewMarketPitch's Longevity report.When did money start pouring into longevity startups? In 2026. Nine months brought $1.7B, already more than all of 2025 ($1.3B). Two rounds, NewLimit’s and Neko’s, made 66% of it. Chart from NewMarketPitch's Longevity report.Who is fighting whom in the longevity market today? Function leads blood tests, Life Biosciences reprogramming in people, Lilly GLP-1 sales. Body scans are split, and Loyal is alone on dog lifespan. Chart from NewMarketPitch's Longevity report.

Every funding round, every investor, and who is really ahead in longevity, in one document. Have a look ↓

Summary

Neko Health is currently the fastest-growing dedicated longevity startup based on recent operating evidence. Its annual scan volume multiplied sixfold in 2025, while Function Health remains its closest challenger and Oura leads the broader market in disclosed revenue and commercial scale.

Neko's growth is particularly striking because every assessment requires a physical clinic, medical staff and specialized equipment. The company went from 10,000 cumulative scans in January 2025 to more than 100,000 by July 2026, while expanding from Sweden into the United Kingdom and United States.

Demand is running well ahead of Neko's capacity. More than 350,000 people had registered or joined its waiting list by July 2026, over three times its cumulative completed scans. That creates a substantial expansion opportunity, although waiting-list registrations are not guaranteed paying customers.

Function Health has an equally compelling claim to growth leadership. Its membership increased approximately fivefold between May 2024 and May 2025, while independent research estimated that its annual revenue run rate rose around 450% in the year to February 2025. Its laboratory-based model also makes expansion less dependent on opening dedicated clinics.

Oura is already operating on another financial level. Revenue reached $1.2145 billion during the nine months ended June 2026, up 74% year over year, while its paying membership doubled to five million. Its profitability and subscription retention make it the strongest documented commercial business in this comparison.

WHOOP is growing rapidly too, with 103% bookings growth during 2025 and more than 2.5 million members by March 2026. But bookings and recognized revenue are different measures, and Oura still has roughly twice WHOOP's last reported membership count.

Neko's valuation has expanded almost as dramatically as its operations. Its July 2026 financing reportedly valued the company near $7 billion, approximately four times its January 2025 valuation. Without a detailed revenue history, however, it is impossible to determine whether its financial performance has kept pace.

Customer retention could become more important than headline growth. Neko reports that approximately 75% of customers prebook another annual scan, while Oura discloses roughly 85% twelve-month paid-member retention. Oura's longer subscription history provides stronger evidence of repeat spending.

Longevity biotechnology is advancing on a different timetable. Life Biosciences began testing its experimental cellular rejuvenation treatment in humans in June 2026, but its first results involve only three patients. No company has yet demonstrated that an approved commercial anti-aging treatment can reliably extend human lifespan.

The next phase of competition will depend on scalability and unit economics. Neko must turn its waiting list into profitable clinic capacity, Function must sustain membership growth and retention, and Oura must keep expanding its recurring revenue. Neko leads in recent dedicated longevity-service expansion, but the long-term commercial winner is far from settled.

Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us

Which checkup startups have the most members? Function Health says it has the most, 500,000+ members, ahead of Prenuvo’s 110,000+. None of them publishes how many members pay today. Chart from NewMarketPitch’s Longevity report.
Longevity reportThis page and 70+ morePDF Get the report

This is just a preview page. Don’t worry if a number looks old: the report gets refreshed, and you’ll always get the latest version.

Why are longevity startups growing so fast right now?

Longevity startups are growing quickly because preventive healthcare has become something consumers are willing to pay for today, even though treatments that actually reverse aging remain largely experimental.

Neko Health, Function Health, Oura and WHOOP are benefiting from this shift. Neko offers preventive health assessments, Function combines blood testing with medical insights, and Oura and WHOOP sell devices that continuously track health indicators. All four have found customers willing to spend money on understanding their health before serious problems appear.

The investment figures are remarkable. Neko raised $260 million in January 2025 and another $700 million in July 2026. Function announced a $298 million Series B in November 2025, followed by $450 million in growth financing in July 2026. WHOOP raised $575 million at a $10.1 billion valuation in March 2026.

Meanwhile, companies developing actual rejuvenation treatments are only beginning human trials. Life Biosciences administered its experimental cellular rejuvenation treatment, ER-100, to its first patient in June 2026.

Two very different markets are developing under the longevity label. Preventive health companies are already collecting substantial revenue, while biotechnology startups are still working toward their first approved treatments.

What makes a longevity startup the fastest-growing?

The fastest-growing longevity startup changes depending on whether we look at revenue, paying customers or completed medical services, and the available evidence currently points to different winners.

Neko Health has some of the strongest evidence of rapid growth in preventive healthcare services. Function Health has shown extraordinary early membership growth, while Oura has published detailed financial figures showing how quickly its much larger business is expanding.

Consider the difference between a company growing from 10,000 to 100,000 customers and another growing from $700 million to $1.2 billion in annual revenue. The first has increased its customer base tenfold. The second has added $500 million in sales. Both are impressive, but they tell us very different things.

The definition of longevity also matters. Oura and WHOOP are primarily wearable technology companies, although their products increasingly focus on preventive health. Neko and Function are more directly involved in preventive medicine. Altos Labs, Retro Biosciences and Life Biosciences are pursuing treatments connected to the biological mechanisms of aging.

For our comparison, we give the most weight to verified growth in paying customers, delivered services and revenue. We also examine funding and clinical progress, but neither tells us how quickly an existing commercial business is actually growing.

Neko or Function: who leads the longevity checkup? Function on people, 500,000+ members, and on sales, ~$100M (an estimate). Neko on money, $960M raised and a ~$7B value. Chart from NewMarketPitch's Longevity report.
Longevity reportThis page and 70+ morePDF Get the report

Just a preview. If a number here looks old, no worries: your report comes with the latest data.

Is Neko Health the fastest-growing longevity startup right now?

Neko Health is currently our strongest candidate for the fastest-growing dedicated longevity startup, with annual scans multiplying sixfold in 2025 and cumulative scans increasing more than tenfold in roughly 18 months.

According to Neko's funding announcements, the company had completed 10,000 scans by January 2025 and more than 100,000 by July 2026. That represents at least 90,000 additional scans over approximately a year and a half.

More importantly, Neko reported performing six times as many scans in 2025 as in 2024. That is a huge increase for a business that needs physical clinics, trained medical staff and specialized scanning equipment. Unlike an app, Neko cannot serve thousands of additional customers simply by allowing them to create an account.

Demand has grown alongside capacity. In January 2025, Neko reported more than 100,000 people waiting for a scan. By July 2026, more than 350,000 people had registered or joined its waiting list. Those figures do not represent guaranteed future customers, but they show how much interest the company has generated.

Neko has also expanded beyond Sweden, opening locations in the United Kingdom before entering the United States with its first New York clinic in September 2026.

The missing piece is revenue. Neko has not released a detailed annual revenue history that would allow us to calculate a reliable growth rate and compare it with every other longevity startup. Still, its increase in completed medical assessments is one of the clearest examples of rapid expansion in the sector.

If you want more recent data on this point, please see our latest longevity market report.

How fast is Neko Health growing compared with other longevity startups?

Neko Health is growing exceptionally fast in completed scans, but Function Health has reported even faster early revenue growth, while Oura is adding much more revenue in absolute dollars.

The comparison becomes interesting when we look beyond headline percentages.

Neko's annual scan volume multiplied sixfold in 2025. Function's membership increased approximately fivefold between May 2024 and May 2025, while Sacra estimated that its annual revenue run rate grew around 450% in the year to February 2025.

Oura offers a much larger financial baseline. Its fiscal 2025 revenue increased 123% to $907.9 million, according to its SEC registration filing. Revenue then grew another 74% year over year during the nine months ended June 2026.

WHOOP reported 103% annual growth in bookings during 2025, ending the year at a $1.1 billion bookings run rate.

These measures cover different periods, and cumulative scans, membership, revenue and bookings cannot be treated as interchangeable. Still, the figures show just how quickly several different longevity-related business models are expanding.

Company Growth measure Reported growth Period
Neko Health Annual scans delivered 6x 2025 vs. 2024
Neko Health Cumulative scans 10x+ Jan. 2025-Jul. 2026
Function Health Membership base Approximately 5x May 2024-May 2025
Function Health Estimated revenue run rate Approximately 450% Year to Feb. 2025
Oura Fiscal revenue 123% FY2025 vs. FY2024
Oura Nine-month revenue 74% Nine months to Jun. 2026
Oura Paid membership Approximately 100% Jun. 2025-Jun. 2026
WHOOP Annual bookings 103% Calendar 2025

Could Function Health actually be growing faster than Neko Health?

Function Health could be growing faster than Neko Health, and its earlier numbers suggest that it was one of the fastest-growing consumer longevity businesses in the market.

According to Sacra's research, Function reached an estimated $100 million annual revenue run rate in February 2025, approximately 450% higher than a year earlier. Its membership reportedly increased from around 40,000 in May 2024 to more than 200,000 in May 2025.

That works out to roughly 160,000 additional members in twelve months. For a relatively young preventive healthcare platform, it was a remarkable expansion.

Function also has an advantage over Neko when it comes to serving additional customers. Its original testing service uses existing laboratory networks, allowing the company to expand without building a dedicated medical center for every new market.

The company has since moved into other services. Its acquisition of Ezra added medical imaging, while its second-quarter 2026 acquisitions of Getlabs' nationwide blood-draw network and SuppCo expanded its collection capabilities and supplement-related offerings.

Function also secured $450 million from General Catalyst's Customer Value Fund in July 2026. The structure was designed around customer acquisition economics rather than functioning as a conventional venture equity round.

What we still need is a more recent, comparable set of membership and revenue figures. Function's earlier growth was extraordinary, but we cannot confidently say that it continues to grow faster than Neko today.

Is Oura actually growing faster than longevity startups like Neko Health?

Oura is currently growing at a much larger revenue scale than the dedicated longevity startups we examined, and its financial disclosures make that growth easier to verify.

According to Oura's September 2026 SEC registration, revenue increased from $406.8 million in fiscal 2024 to $907.9 million in fiscal 2025, a 123% increase.

The company then generated $1.2145 billion during the nine months ended June 2026, compared with $697.6 million during the same period a year earlier. That represents an additional $517 million in revenue, or 74% growth.

To put that into perspective, Oura added more revenue in those nine months than Function Health's entire estimated annual revenue run rate in early 2025.

Its customer base is growing rapidly too. Oura reported five million paying members in June 2026, twice the 2.5 million reported one year earlier. Membership revenue increased from $108.8 million to $240.5 million across the comparable nine-month periods, roughly 121% growth.

Oura therefore combines two advantages that rarely appear together: a business already generating more than $1 billion in annual revenue and a customer base that is still expanding at a very high rate.

We would rank Oura ahead of Neko on disclosed revenue scale and absolute revenue growth. However, Oura primarily sells smart rings and health-monitoring subscriptions, so calling it the fastest-growing pure-play longevity startup would stretch the definition.

If you want more recent data on this point, please see our latest longevity market report.

How fast are the top longevity startups rising in value? Fast. Function’s value rose ~10 times in 17 months, to $2.5B. Neko and NewLimit nearly quadrupled in 13 to 18 months, NewLimit with no drug in people. Chart from NewMarketPitch's Longevity report.
Longevity reportThis page and 70+ morePDF Get the report

This is a preview page. Spotted an outdated number? That’s normal here. The report you get is always the freshest version.

Is WHOOP catching up with Oura?

WHOOP is growing quickly, but Oura currently has a larger disclosed paying customer base and stronger evidence of its actual revenue scale.

In March 2026, WHOOP announced a $575 million funding round at a $10.1 billion valuation. The company reported more than 2.5 million members, 103% growth in bookings during 2025 and a $1.1 billion bookings run rate at the end of that year.

WHOOP also said it operated cash-flow positive during 2025, an encouraging achievement for a company expanding its hardware and subscription business.

Oura, meanwhile, reported five million paid members by June 2026 and approximately $1.4 billion in trailing-twelve-month revenue, based on its SEC filings.

The financial comparison needs care. WHOOP's bookings run rate represents annualized commercial commitments at a particular point, whereas Oura's figure represents recognized revenue over twelve months. We cannot subtract one from the other and call the difference a sales lead.

The companies also sell subscriptions differently. WHOOP bundles access to its wearable technology and services through membership plans, while Oura collects upfront hardware revenue alongside subscription payments.

Still, Oura has roughly twice WHOOP's last reported membership count. WHOOP is a serious competitor, especially in performance monitoring, but the available figures do not show that it has caught up.

Is Neko Health's $7 billion valuation growing faster than its business?

Neko Health's valuation has climbed extraordinarily fast, but we cannot yet tell whether its revenue has increased at a similar pace.

According to the Financial Times, Neko's July 2026 financing valued the company at nearly $7 billion, approximately four times the valuation associated with its January 2025 round.

Across those two financings, Neko raised $960 million. Its latest $700 million round was also about 2.7 times larger than the preceding $260 million investment.

There is genuine operating growth behind that enthusiasm. Neko's delivered scan volume has increased sharply, its waiting list has expanded, and the company has entered several new markets. But its valuation now reflects expectations about what those clinics could eventually generate.

At the standard UK scan price of £299, 100,000 assessments would represent £29.9 million if all were sold at that price. This is only an illustration, because Neko's reported scan total covers multiple years and countries, with potentially different pricing.

Without annual revenue and profitability figures, we cannot calculate a meaningful revenue multiple or determine whether investors are paying too much.

The interesting development is the speed at which investors have committed capital. Neko went from a $260 million fundraising round to a $700 million round in approximately 18 months, while expanding a healthcare model that still depends heavily on physical locations.

If you want more recent data on this point, please see our latest longevity market report.

How fast is Neko Health growing, clinic by clinic? Fast, from one clinic in Stockholm in 2023 to nine in Sweden, the UK and New York, with 100,000+ people scanned by July 2026. Miami and a second New York clinic are planned by January 2027. Chart from NewMarketPitch’s Longevity report.
Longevity reportThis page and 70+ morePDF Get the report

Preview only. Some numbers may have changed since we made this page, but your report will be up to date.

Are Neko Health and Oura getting customers to come back?

Neko Health and Oura have reported encouraging customer retention figures, although Oura currently has stronger evidence of repeat payments over time.

Neko reported in July 2026 that approximately 75% of customers book and prepay for their next annual scan before leaving their appointment. That suggests customers see enough value in the service to commit to another assessment.

However, we should distinguish advance bookings from completed repeat visits. Neko still needs several years of customer data to establish how many people continue paying for annual scans over the long term.

Oura already has a much longer subscription history. Its SEC filing reported approximately 85% weighted-average twelve-month paid-member retention as of June 2026. Roughly 65% of its monthly active members used the app daily.

Those figures are particularly relevant because Oura's subscription revenue has become increasingly important to its business. It can generate repeat payments from existing members without selling them another ring every year.

Function has also built its service around ongoing health monitoring, but it has not publicly disclosed a similarly detailed multiyear renewal series.

Of the three, Oura currently offers the clearest proof that consumers continue paying after their initial purchase. Neko's annual prebooking figure looks promising, but it is still too early to put it on the same level.

Can Neko Health keep growing when every new customer needs a clinic?

Neko Health has shown that its clinic-based model can expand internationally, but opening enough locations to satisfy demand will remain one of its biggest challenges.

Neko launched its first scanning service in Sweden in February 2023 and entered the United Kingdom in September 2024. By early 2026, it reported six locations across Sweden and the UK, with additional sites opened or announced as its network grew.

Its first American clinic opened in Manhattan in September 2026. Before the opening, an August 2026 TechCrunch report said more than 25,000 people were already on the New York waiting list.

The demand is encouraging, but delivering the service is more complicated than distributing a software product. Every new clinic needs specialized equipment, qualified medical professionals, suitable premises and enough appointments to cover its operating costs.

The unanswered question concerns the economics of each location. We need to know how quickly a clinic reaches full capacity, how much revenue it generates and how long it takes to recover its initial investment.

Until those figures become public, Neko's international expansion is impressive, but we still cannot say how easily hundreds of clinics could be added.

Which body-scan startups scan the most people? Prenuvo publishes the biggest count, 200,000+ MRI scans done by September 2026. Neko says 100,000+ people scanned by July 2026, while Ezra and Craft Body Scan publish no count. Chart from NewMarketPitch’s Longevity report.
Longevity reportThis page and 70+ morePDF Get the report

This is just a preview page. Don’t worry if a number looks old: the report gets refreshed, and you’ll always get the latest version.

Are people signing up for longevity services faster than companies can serve them?

Neko Health currently has the clearest evidence that demand for its longevity services exceeds delivery capacity, while Function Health and Oura have demonstrated faster customer expansion through models that are easier to distribute.

The numbers help explain the difference.

Neko had completed more than 100,000 cumulative scans by July 2026, while over 350,000 people had registered or joined its waiting list. Its reported demand pipeline was therefore more than three times its entire historical scan volume.

Function's membership had increased by approximately 160,000 people in twelve months during its earlier growth phase. Rather than operating dedicated scanning centers, the company was able to rely on established laboratory infrastructure.

Oura has reached a different scale altogether. Its membership increased from 2.5 million in June 2025 to five million in June 2026, adding approximately 2.5 million paying members in one year.

That means Oura added roughly fifteen times as many members in absolute terms as Function did during its previously reported twelve-month growth period, although the companies sell very different products.

Neko's waiting list indicates how much additional demand the company may be able to convert as it opens clinics. Yet waiting-list registrations are not confirmed bookings, and customers could lose interest if appointments remain unavailable for too long.

Company Earlier reported scale Later reported scale What the figures show
Neko Health 10,000 cumulative scans, Jan. 2025 100,000+ cumulative scans, Jul. 2026 At least 10x cumulative volume
Function Health Approximately 40,000 members, May 2024 200,000+ members, May 2025 Around 5x membership
Oura 1.3M paid members, Sep. 2024 2.9M, Sep. 2025 Approximately 123% growth
Oura 2.5M paid members, Jun. 2025 5.0M, Jun. 2026 Approximately 100% growth
WHOOP Earlier comparable count not disclosed here 2.5M+ members, Mar. 2026 Large scale, growth rate unverified
Neko Health 100,000+ waiting, Jan. 2025 350,000+ registered or waiting, Jul. 2026 Demand pipeline, not active customers
Neko Health 2024 annual scan baseline 6x the 2024 annual volume in 2025 Rapid growth in completed services

Are longevity biotech startups growing as fast as Neko Health and Function Health?

Longevity biotechnology startups are making real scientific progress, but their businesses are still much earlier in development than Neko Health, Function Health or Oura.

Life Biosciences offers one of the best examples. In January 2026, the FDA cleared the company's investigational new drug application for ER-100, a partial epigenetic reprogramming therapy being developed for optic neuropathies. The company administered the treatment to its first patient in June.

By October 2026, Life Biosciences had reported early results from three glaucoma patients at its first dose level. The company said treatment was tolerated through day 56 and that two participants showed preliminary improvements in visual-field measurements.

That is a meaningful clinical milestone, although three patients and a short observation period are nowhere near enough to prove that the treatment works.

Retro Biosciences has also advanced. In May 2026, the company announced an initial financing close at a $1.8 billion pre-money valuation and said its RTR242 program had progressed from choosing a clinical indication to first-in-human dosing in approximately 15 months.

BioAge Labs, a publicly traded company, advanced its BGE-102 inflammation program into Phase 2 testing in June 2026. It is targeting diseases connected to metabolic aging.

These developments show that longevity biotechnology is moving into human clinical testing. But these companies have yet to develop approved anti-aging treatments generating recurring commercial sales.

We can compare their progress toward clinical approval, but applying consumer revenue-growth rankings to them would produce a misleading result.

Is Neko Health, the body-scan startup, really worth $7 billion? Not on sales, mostly on promise. Neko sold ~$16M of body scans in 2025 and lost ~$70M. At ~$7B, it is valued at 430 times its sales. Chart from NewMarketPitch's Longevity report.
Longevity reportThis page and 70+ morePDF Get the report

Just a preview. If a number here looks old, no worries: your report comes with the latest data.

Is Life Biosciences closest to delivering an actual anti-aging treatment?

Life Biosciences is currently one of the more advanced companies testing cellular rejuvenation in humans, although its early results cannot establish that it has developed an effective anti-aging treatment.

Its ER-100 program uses controlled expression of three reprogramming factors, OCT4, SOX2 and KLF4, to investigate whether damaged cells can recover aspects of more youthful function.

The initial treatment targets optic neuropathies, including glaucoma, rather than aging throughout the entire body.

After receiving FDA clearance in January 2026, Life Biosciences dosed its first patient in June and reported initial observations from three treated participants in October.

According to the company, there were no serious adverse events attributable to treatment through the first 56 days. Two patients also showed preliminary improvements in visual-field measurements, and the trial's safety monitoring committee recommended progressing to a higher dose.

A three-person early-stage study without a randomized comparison cannot show that cellular reprogramming produces lasting rejuvenation. The improvements could also change as more patients are enrolled and follow-up continues.

Still, getting an experimental rejuvenation therapy into human clinical testing is a substantial achievement. Life Biosciences deserves attention for that progress, even though its current commercial growth cannot be compared with the millions of paying members reported by consumer health companies.

Do longevity startups actually help people live longer?

No leading consumer longevity startup has yet demonstrated through definitive long-term clinical evidence that its commercial service increases human lifespan, despite the rapid growth in customers and investment.

Neko Health has reported some encouraging medical findings. In July 2026, it said that approximately three-quarters of returning customers who had previously been identified with severe or life-threatening conditions were subsequently in good health or had those conditions under control.

Neko also reported statistically significant improvements in five of seven key biomarkers between initial and follow-up scans.

Those results suggest that identifying health problems may help people seek treatment and improve certain health indicators. However, we cannot tell how much of the improvement would have occurred without the scans, because the reported observations do not come from a randomized trial measuring mortality or long-term outcomes.

There are broader concerns around preventive screening. In July 2026, the Radiological Society of North America discussed the rapid expansion of commercial whole-body MRI screening despite unresolved questions about benefits and possible downstream harms.

The American College of Radiology has also said that evidence is insufficient to recommend total-body MRI screening for asymptomatic people without relevant risk factors. Neko uses a different scanning system, but preventive screening services can face similar questions about unnecessary follow-up examinations and whether detecting more abnormalities actually improves health.

Oura and WHOOP face a different challenge. Their devices provide detailed information about sleep, activity and physiological signals, but regular monitoring does not automatically translate into longer life.

For now, these products are proving their commercial appeal much faster than their ability to extend lifespan. That's a pretty big distinction for an industry built around longevity.

If you want more recent data on this point, please see our latest longevity market report.

Could Function Health eventually overtake Neko Health?

Function Health could eventually become a larger longevity business than Neko Health because it can add customers and services without building an entire network of dedicated scanning centers.

Function began with comprehensive laboratory testing, then expanded into medical imaging, at-home blood collection and supplement-related services.

Its acquisitions of Ezra, Getlabs' blood-draw network and SuppCo show how the company is trying to build a broader preventive healthcare platform around an existing customer relationship.

Neko has chosen a more integrated approach, combining proprietary scanning technology with physical medical centers. It controls the experience more closely, but every major expansion requires additional clinic capacity.

Function's model could therefore reach more customers with less physical infrastructure, especially if its laboratory partnerships and collection network continue expanding.

The financial outcome will depend heavily on customer retention, acquisition costs and the profitability of the additional services. Function has not disclosed enough recent figures to establish that its model is already more profitable.

Function's previous fivefold annual membership growth shows what the company can achieve. If it can maintain strong customer growth while increasing revenue per member, it has a realistic chance of becoming the larger dedicated preventive longevity platform.

Can Neko Health keep growing this fast?

Neko Health can probably keep adding customers rapidly, but repeating its sixfold annual scan growth will become much harder as its clinic network gets bigger.

The mathematics are demanding. Repeating sixfold growth for two consecutive years would mean delivering 36 times as many scans as at the beginning of that period.

That becomes increasingly challenging when the company needs physical facilities and medical staff for each additional appointment.

Neko does have a substantial customer pipeline. As discussed earlier, its reported registrations and waiting list already exceed its cumulative completed scans by a wide margin. That should give new clinics a pool of prospective customers to serve.

The company is also entering markets where it has limited operating history. Its New York launch introduces different medical regulations, staffing costs and customer expectations from those in Sweden and the United Kingdom.

Repeat customers could help stabilize revenue. If Neko's reported 75% annual prebooking rate eventually translates into completed return visits, existing customers would account for an increasing share of appointments.

The important question for the next stage is how many additional scans Neko can deliver each year, rather than whether it can maintain the same percentage growth from a small starting base.

A company moving from 100,000 to 200,000 annual scans would add 100,000 services while growing 100%. Moving from 200,000 to 350,000 would add even more services despite a lower 75% growth rate. Slower percentage growth would not necessarily mean the business was losing strength.

When did money start pouring into longevity startups? In 2026. Nine months brought $1.7B, already more than all of 2025 ($1.3B). Two rounds, NewLimit’s and Neko’s, made 66% of it. Chart from NewMarketPitch's Longevity report.
Longevity reportThis page and 70+ morePDF Get the report

This is a preview page. Spotted an outdated number? That’s normal here. The report you get is always the freshest version.

Which longevity startup has the best business model for long-term growth?

Oura currently has the strongest publicly documented combination of revenue growth, recurring payments and profitability among the longevity-related companies we examined.

Its SEC filing reported $60.8 million in net income during the nine months ended June 2026, compared with $1.6 million in the corresponding previous period.

Gross margin improved from approximately 51% to 55% while revenue increased 74%. That is particularly encouraging because Oura managed to improve profitability while continuing to grow at a high rate.

Membership revenue increased approximately 121% during the same period, compared with 65% growth in hardware revenue. Subscriptions consequently increased from around 16% to 20% of total revenue.

Hardware still represents the majority of Oura's sales, but the company has built a recurring revenue stream supported by millions of paying members.

Neko's model could also become attractive. The Financial Times reported in July 2026 that clinics operating for more than six months were profitable on a gross-margin basis, according to the company.

That is encouraging, although clinic-level gross-margin profitability does not tell us whether Neko is profitable overall or how quickly new centers recover their opening costs.

Function's original laboratory-based service requires less dedicated infrastructure, but its current margins and acquisition costs remain difficult to assess from public information.

Oura has the clearest financial evidence today. Neko and Function may eventually produce equally attractive businesses, but investors and outside researchers still have much less visibility into their economics.

Which longevity startup is growing the fastest overall?

Neko Health is currently our strongest choice for the fastest-growing dedicated longevity startup, while Function Health remains its closest challenger and Oura leads the broader market in publicly documented revenue scale.

Neko has demonstrated an unusually strong combination of service growth, customer demand and international expansion. Its annual scan volume multiplied sixfold in 2025, and it moved from a relatively small Swedish operation into the United Kingdom and United States within a few years.

Function Health's earlier numbers were arguably even more impressive in percentage terms. Membership grew roughly fivefold over twelve months, and Sacra estimated that its revenue run rate increased approximately 450% in the year to February 2025. However, its more recent growth is harder to verify without updated financial and membership disclosures.

Oura is the most financially proven business in the comparison. Its nine-month revenue reached $1.2145 billion through June 2026, up 74% year over year, while its paid membership doubled to five million. No other company in our comparison has disclosed an equally strong combination of commercial scale, growth and profitability.

Neko has the strongest recent evidence of rapid operating expansion among dedicated preventive longevity startups, but the available disclosures do not establish a definitive percentage-revenue-growth winner across the entire sector.

If we include broader health-monitoring technology, Oura is the stronger commercial leader. If we focus on companies developing treatments that might reverse aspects of aging, Life Biosciences is worth watching for its clinical progress, but that is a different race.

For now, Neko Health best represents how quickly dedicated longevity services are growing. The much bigger question is whether its growing clinic network can eventually produce a business with the revenue scale, repeat payments and profitability that Oura has already demonstrated.

If you want more recent data on this point, please see our latest longevity market report.

Who is fighting whom in the longevity market today? Function leads blood tests, Life Biosciences reprogramming in people, Lilly GLP-1 sales. Body scans are split, and Loyal is alone on dog lifespan. Chart from NewMarketPitch's Longevity report.
Longevity reportThis page and 70+ morePDF Get the report

Preview only. Some numbers may have changed since we made this page, but your report will be up to date.

Our methodology

This analysis identifies the fastest-growing longevity startup using the latest available evidence through October 2026. We compare Neko Health, Function Health, Oura and WHOOP on commercial growth, customer adoption, operating expansion, financial performance and scalability. We also examine longevity biotechnology companies separately to account for clinical development progress.

We prioritize measurable operating activity over fundraising announcements or company valuations. Annual completed scans, paying customers, revenue, subscription retention and profitability provide different views of growth. We compare each measure within its reported period and distinguish cumulative activity from annual growth, waiting-list demand from paying customers, and bookings from recognized revenue.

We assess growth rates alongside absolute expansion and commercial maturity. A sixfold increase from a small operating base does not establish greater financial scale than a business adding hundreds of millions of dollars in revenue. We also consider the infrastructure needed for growth, including Neko's clinics, Function's laboratory network and the recurring hardware-and-subscription models operated by Oura and WHOOP.

We use company disclosures for reported operating milestones, regulatory filings for financial performance, and independent financial research where audited public figures are unavailable. Function Health's estimated revenue growth comes from Sacra and is treated as an independent estimate. Neko's scan growth and customer prebooking figures are company-reported. Oura's revenue, profitability, membership and retention figures come from its SEC registration documents.

Longevity biotechnology is evaluated using clinical milestones rather than consumer growth measures. We distinguish FDA authorization to begin a clinical trial from evidence of treatment effectiveness, and we treat preliminary company-reported observations as early clinical findings. Claims about longer lifespan require stronger evidence than improvements in biomarkers or short-term physiological measurements.

Key sources for Neko Health include Neko Health's January 2025 Series B announcement, its January 2026 U.S. expansion update, its July 2026 Series C announcement and operating figures, and its September 2026 New York opening announcement.

For Function Health, we used Sacra's analysis of its estimated $100 million annual revenue run rate, Sacra's company research and membership estimates, and Function Health's official platform and financing announcement. For the wearable companies, we relied primarily on Oura's September 2026 SEC registration statement and WHOOP's March 2026 Series G announcement.

For longevity biotechnology, the main references are Life Biosciences' January 2026 FDA clearance announcement, the ER-100 clinical trial registry, its October 2026 first-in-human results, Retro Biosciences' May 2026 financing and development update, and BioAge Labs' June 2026 clinical development announcement. We also considered the American College of Radiology's position on screening total-body MRI when evaluating claims about preventive health screening.

Our conclusion gives the greatest weight to recent demonstrated growth, supported by multiple operating measures where available. The resulting comparison identifies the strongest evidence of growth leadership without treating fundamentally different business models or unverified future expectations as equivalent.

Which checkup startups have the most members? Function Health says it has the most, 500,000+ members, ahead of Prenuvo’s 110,000+. None of them publishes how many members pay today. Chart from NewMarketPitch’s Longevity report.
Longevity reportThis page and 70+ morePDF Get the report

This is just a preview page. Don’t worry if a number looks old: the report gets refreshed, and you’ll always get the latest version.